Business● Low2h ago · Nov 4, 2026, 5:46 AM
Ultragenyx outlines 2027 profitability plan with R&D under $350M and SG&A under $375M following GTX-102 discontinuation
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Ultragenyx has detailed its plan for achieving profitability by 2027, setting specific targets for R&D and SG&A spending after discontinuing a particular drug. This outlines the company's strategic financial direction.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business21m agoNaidu writes to Piyush Goyal on 150 chilli containers held at Colombo port over moisture contentThe HinduBusiness24m agoTORM GAAP EPS of $1.91, revenue of $499M beats by $143.39M; raises FY2026 outlookSeeking Alpha TechBusiness32m agoAI stocks tied to Texas data center boom slide after Hinojosa winSeeking Alpha TechBusiness35m agoBayerische Motoren Werke Aktiengesellschaft GAAP EPS of €2.46, revenue of €30.45BSeeking Alpha Tech